Mereo BioPharma Group plc · NASDAQ:MREO
Mereo BioPharma — Investor Presentation (August 2022)
18 slides from Mereo BioPharma's investor presentation, August 2022
Slide 1: Unlocking The Potential Of Novel Targets For Rare Diseases And Cancer
Unlocking The Potential Of Novel Targets For Rare Diseases And Cancer August 2022 Mereo BioPharma Group plc NASDAQ: MREO
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Mereo BioPharma Group plc (the “Company”) solely for your information and for the purpose of providing background information on the Company, its business and the industry in which it operates or any particular aspect thereof. For the purposes of thi
Slide 3: Mereo BioPharma – A Rare Disease and Oncology Company
Mereo BioPharma – A Rare Disease and Oncology Company Our Mission To improve the lives of patients with rare diseases and cancer Strategic principles guiding us on our journey… Partner programs where it makes Acquire and develop programs in rare Focus on our core competencies and strategic sense and
Slide 4: Mereo BioPharma – A Mid-Late-Stage Company with Validating Partnerships
Mereo BioPharma – A Mid-Late-Stage Company with Validating Partnerships • Pipeline of 3 programs in rare disease/oncology all with advanced clinical data o Setrusumab for Osteogenesis Imperfecta (OI) under the Ultragenyx partnership, has entered a registrational trial in Q2 2022 o Alvelestat for Alp
Slide 5: Setrusumab – In Late-Stage Development for the Treatment of OI
Setrusumab – In Late-Stage Development for the Treatment of OI Setrusumab Overview • Anti-sclerostin antibody under investigation for the treatment of OI, a rare genetic bone disease with high unmet need and no approved therapies • Setrusumab promotes bone formation and inhibits bone resorption • Gl
Slide 6: OI – A Rare Genetic Bone Condition with No Approved Standard of Care
OI – A Rare Genetic Bone Condition with No Approved Standard of Care Osteogenesis Imperfecta High Unmet Need • Symptoms include frequent bone fractures, skeletal deformities, pain, • A rare genetic bone disease, mostly linked respiratory and gastric problems to a mutation in Type I collagen1,2 • No
Slide 7: Summary of Phase 2b ASTEROID Results in Adults with OI Types I, III and IV
Summary of Phase 2b ASTEROID Results in Adults with OI Types I, III and IV Statistically Significant Dose-Dependent Increases in Areal BMD by DXA Following 12 Months of Setrusumab Therapy Lumbar Spine Mean (SEM) Change From Baseline at Month 12, % 12 Total Hip Femoral Neck *** 10 6 * *** ** 8 4 ** 6
Slide 8: Ultragenyx – Mereo Partnership and Long Term Plan
Ultragenyx – Mereo Partnership and Long Term Plan Mereo – Ultragenyx Partnership Clinical Development Overview Mereo Territories & Focus • Ultragenyx funding and leading • Mereo’s current focus is laying the global development plan in • Phase 2/3 pediatric study in OI groundwork for reimbursement of
Slide 9: Alvelestat – In Development for the Treatment of AATD-LD and BOS
Alvelestat – In Development for the Treatment of AATD-LD and BOS* Alvelestat Overview • Neutrophil elastase (NE) is a protease enzyme that unopposed is believed to drive lung tissue destruction in lead indication, AATD-LD and, also in GVHD BOS • Alvelestat is a highly specific neutrophil elastase in
Slide 10: AATD-LD – A Rare Progressive Lung Disease with High Unmet Need
AATD-LD – A Rare Progressive Lung Disease with High Unmet Need Alpha-1 antitrypsin (AAT) inhibits the action of neutrophil elastase. Individuals who lack AAT or produce misfolded inactive AAT are at risk from progressive lung damage and early onset emphysema. AATD-LD High Unmet Need Significant Mark
Slide 11: Linking Biomarkers to Pathological Pathway
Linking Biomarkers to Pathological Pathway AATD-Lung Disease Pathogenic Pathway Biomarkers of AATD-LD Blood NE Aα-Val360 Desmosine CT Density/FEV1 Elastase Activity Unopposed NE Alveolar Elastin Lung Tissue Breakdown Loss/Emphysema Increased elastase Increase in elastase- Elastin breakdown activity
Slide 12: ASTRAEUS – A 12-week Study of Alvelestat in AATD-Related COPD
ASTRAEUS – A 12-week Study Treating Participants Who Have alpha-1 antitrypsin- related COPD With Alvelestat (MPH966) or Placebo (NCT03636347) • A randomized double blind-placebo-controlled study in patients naïve to augmentation or following a 6-month wash-out period. Comparing placebo and two diffe
Slide 13: Etigilimab – An Anti-TIGIT Antibody, in Development in Combination with an Anti-PD-1 Antibody
Etigilimab – An Anti-TIGIT Antibody, in Development in Combination with an Anti- PD-1 Antibody Etigilimab Summary • An IgG1 monoclonal antibody designed to balance affinity and ADCC characteristics while limiting side effects • Pharmacodynamic changes consistent with target engagement Etigilimab Pro
Slide 14: ACTIVATE Trial – Preliminary Efficacy Data
ACTIVATE Trial – Preliminary Efficacy Data Response summary (efficacy analysis set; n=38)* Objective Cohort Responses by RECIST A C E F (Rare) F (Rare) F (Rare) H Total Endometrial Cervical TMB-H/MSS Uveal Sarcoma GCT Ovarian Cancer Cancer (HGSOC) (CPI-naïve) (n=1) (n=5)^ (n=6) (n=6) (n=7) (n=4) (n=
Slide 15: Partnerships Overview
Partnerships Overview Current Partnerships • Ultragenyx leads global development of setrusumab, Mereo retains rights to Setrusumab in Europe and the UK • Received $50 million upfront, up to $254 million in additional milestones plus royalties • Registrational trial initiated • Navicixizumab out-lice
Slide 16: Upcoming Key Milestones & Opportunities
Upcoming Key Milestones & Opportunities Upcoming Milestone For Core Programs Product 2022 2023 2024 Indication Next Milestone Candidate H1 H2 H1 H2 H1 H2 Pediatric Phase 2b/3 ORBIT (5-25 years) Phase 2/3 dosing update & Phase 3 transition Setrusumab OI Pediatric study (2-5 years ) Supportive study i
Slide 17: Roadmap for Growth
Roadmap for Growth Maintain A Strong • Cash runway to late 2024 ($111.4 million at March 31, 2022) 1 Balance Sheet • Active cost management to maintain cash runway • Focus on high value rare disease programs. Allocate R&D capital to key value inflection points. • Alvelestat: Mereo is evaluating opti
Slide 18: Mereo BioPharma Group plc
Mereo BioPharma Group plc One Cavendish Place London, W1G 0QF UK +44 (0)333 0237 300 Mereo Biopharma Group plc
Mereo BioPharma Group — Investor Presentation (August 2022) on 6ix